Breast cancer systemic therapy: The need for more economically sustainable scientific strategies in the world

Breast Care

Volumn 3, Issue 6, 2008, Pages 434-438

  Elzawawy, Ahmed ^a,b,c,d,e  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b Alsoliman Radiation Oncology Unit

^c Port Said General Hospital

^d ICEDOC   (Egypt)

^e ICEDOC and ICEDOC's Experts in Cancer Without Borders ^*  (United States)

Author keywords

Breast cancer; Cancer chemotherapy; Cancer control; Health economics; Low and middle income countries; Treatment

Indexed keywords

BREAST CANCER; CANCER CENTER; CANCER CONTROL; CANCER INCIDENCE; CANCER PATIENT; CANCER RESEARCH; CANCER THERAPY; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG INDUSTRY; HUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY;

EID: 58149382259     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000170233     Document Type: Review

References (44)

1. Stewart BW, Kleihues P: World Cancer Report. Lyon, France, IARC Press, 2003.
2. Yach D, Hawkes C, Gould CL, Hofman KJ: The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004;291:2616-2622.
3. Jones SB: Cancer in the developing world: a call to action. BMJ 1999;319:505-508.
4. Iarc Working Group on the Evaluation of Cancer-Preventive Strategies: Iarc Handbooks of Cancer Prevention. Lyon, Oxford University Press, 2002.
5. Sikora K: Developing a global strategy for cancer. Eur J Cancer 1999;35:1870-1877.
6. Porter A, Aref A, Chodounsky Z, Elzawawy A, Manatrakul N, Ngoma T, Orton C, Van't Hooft E, Sikora K: A global strategy for radiotherapy: a who consultation. Clin Oncol (R Coll Radiol) 1999;11:368-370.
7. Ashraf H: Poor nations need more help to slow growing cancer burden: the international atomic energy agency asks donors to provide millions of dollars to buy radiotherapy equipment. Lancet 2003;361:2209.
8. Meropol NJ, Schulman KA: Cost of cancer care: issues and implications. J Clin Oncol 2007;25:180-186.
9. Ferlay J, Bray F, Pisani P, Parkin DM: Globocan 2000. Cancer incidence, mortality and prevalence worldwide, version 1.0, Iarc cancerbase no. 5. Lyon, IARC Press, 2001.
10. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
11. Porter P: 'Westernizing' women's risks? Breast cancer in lower-income countries. N Engl J Med 2008;358:213-216.
12. Carlson RW, Anderson BO, Chopra R, Eniu AE, Jakesz R, Love RR, Masetti R, Schwartsmann G: Treatment of breast cancer in countries with limited resources. Breast J 2003;9(suppl 2):S67-74.
13. Yarney J, Vanderpuye V, Clegg Lamptey JN: Hormone receptor and HER-2 expression in breast cancers among Sub-Saharan African women. Breast J 2008;14:510-511.
14. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
15. National Institute of Health: Trastuzumab for 6 months or 1 year in treating women with nonmetastatic breast cancer that can be removed by surgery, October 2007; clinicaltrials.Gov/show/nct00381901.
16. Lassarat S, Jootar S: Ongoing challenges of a global international patient assistance program. Ann Oncol 2006;17(suppl 8):viii43-viii46.
17. Colleoni M, Maibach R: Breast international group newsletter. 2007;9:22.
18. Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B, Vrankar M: Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 2005;16:1129-1134.
19. Brand R, Capadano M, Tempero M: A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 1997;15:331-341.
20. Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, Possinger K: Prolonged infusion of gemcitabine in stage iv breast cancer: a phase i study. Anticancer Drugs 1999;10:525-531.
21. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK: Maximumtolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997;15: 310-316.
22. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al.: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-498.
23. Ratain MJ, Cohen EE: The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol 2007;25:3397-3398.
24. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nole F, Viale G, Goldhirsch A: Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006;17:232-238.
25. Puozzo C, Gridelli C, Jaworski M: Pharmacokinetics of navelbine oral in elderly patients. Tumori 2002;88:S75-76.
26. Winer EP, Chu L, Spicer DV: Oral vinorelbine (navelbine) in the treatment of advanced breast cancer. Semin Oncol 1995;22:72-78; discussion 78-79.
27. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S, Osterwalder B: Randomised, phase II trial comparing oral capecitabine (xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-1372.
28. Sikora K, Advani S, Koroltchouk V, Magrath I, Levy L, Pinedo H, Schwartsmann G, Tattersall M, Yan S: Essential drugs for cancer therapy: a world health organization consultation. Ann Oncol 1999;10:385-390.
29. WHO: Essential medicines who model list. Retrieved from: www.Who.Int/emlib,August 20, 2008.
30. Garber JE, Richardson A, Harris LN, Miron A, Silver D, Golshan M: New adjuvant cisplatin (cddp) in 'Triple-negative' Breast cancer (bc). San Antonio Breast Cancer Synposium 2006, abstr 3074.
31. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13:73-80.
32. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-9318.
33. Zanger UM, Raimundo S, Eichelbaum M: Cytochrome p450 2d6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37.
34. Toscano C, Klein K, Blievernicht J, Schaeffeler E, Saussele T, Raimundo S, Eichelbaum M, Schwab M, Zanger UM: Impaired expression of cyp2d6 in intermediate metabolizers carrying the *41 allele caused by the intronic snp 2988g>a: evidence for modulation of splicing events. Pharmacogenet Genomics 2006;16:755-766.
35. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient cyp2d6 and cyp2c19 genotypes. J Clin Oncol 2007;25:5187-5193.
36. Punglia RS, Winer EP, Weeks JC, Burstein HC: Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis. ASCO Ann Meet Proc Part 1, 2007,vol 25, pp. 502.
37. Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U, Decensi AU: Polymorphism in the cyp2d6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the italian tamoxifen trial. J Clin Oncol 2006;24:3708-3709; author reply p. 3709.
38. Elzawawy AM, Elbahaie AM, Dawood SM, Elbahaie HM, Badran A: Delay in seeking medical advice and late presentation of female breast cancer patients in most of the world. Could we make changes? The experience of 23 years in Port Said, Egypt. Breast Care 2008;3:37-41.
39. WHO: National Cancer Control Programmes: Policies and Managerial Guidelines. Geneva, WHO, 2002.
40. Mellstedt H: Cancer initiatives in developing countries. Ann Oncol 2006;17(suppl 8):viii24-viii31.
41. Olopade OI, Schwartsmann G, Saijo N, Thomas CR Jr: Disparities in cancer care: a worldwide perspective and roadmap for change. J Clin Oncol 2006;24:2135-2136.
42. Brauch H, Schroth W, Eichelbaum M, Schwab M, Harbeck N: Clinical relevance of cyp2d6 genetics for tamoxifen response in breast cancer. Breast Care 2008;3:43-50.
43. Siemiatycki J: Commentary: epidemiology on the side of the angels. Int J Epidemiol 2002;31:1027-1029.
44. Chandiwana S, Ornbjerg N: Review of north-south and south-south cooperation and conditions necessary to sustain research capability in developing countries. J Health Popul Nutr 2003;21:288-297.